ADC Therapeutics, Five Prime sign exclusive license agreement for human ... News-Medical.net Under the agreement, ADC Therapeutics plans to initiate preclinical research and development of antibody-drug conjugates using the antibodies licensed from Five Prime immediately, adding to ADC Therapeutics' portfolio of proprietary ADC programs. Five Prime licensing deal propels it into hot antibody-drug conjugate space |
